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Abstract: Systemic lupus erythematosus (SLE) predominantly affects women in their repro-
ductive years. Renal disease (glomerulonephritis) is one of the most frequent and serious 
manifestations of SLE. Of the various histological types of lupus glomerulonephritis, diffuse 
proliferative nephritis carries the worst prognosis. Combined with high-dose prednisone, 
mycophenolate mofetil (MMF) has emerged as a first-line immunosuppressive treatment, 
although data regarding the efficacy of MMF on the long-term preservation of renal function 
are forthcoming. Cyclophosphamide is reserved for more severe forms of lupus nephritis, 
such as crescentic glomerulonephritis with rapidly deteriorating renal function, patients with 
significant renal function impairment at presentation, and refractory renal disease. Evidence for 
the calcineurin inhibitors in the treatment of lupus nephritis is weaker, and it concerns patients 
who are intolerant or recalcitrant to other agents. While further controlled trials are mandatory, 
B cell modulation therapies, such as rituximab, belimumab and epratuzumab are confined to 
refractory disease. Non-immunosuppressive measures, such as angiotensin-converting enzyme 
inhibitors, vigorous blood pressure control, prevention and treatment of hyperlipidemia and 
osteoporosis, are equally important.
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Introduction
Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of 
unknown etiology. In all series of SLE worldwide, women constitute more than 90% 
of all patients. This female preponderance becomes less pronounced before puberty and 
after menopause, which suggests that estrogen metabolism and its link with the immune 
system may play roles in the pathogenesis of the disease.1 An alternative hypothesis 
for the sexual dimorphism of SLE is the skewed inactivation or monosomy of the 
X chromosome, which contains immune-related genes.2 Although the exact pathoeti-
ologic mechanisms have yet to be elucidated, it is believed that the onset of SLE is 
triggered by ill-defined environmental factors in genetically susceptible individuals.
Renal disease is one of the most common and most serious manifestations of SLE. 
Renal involvement in SLE adversely affects its ultimate prognosis in terms of patient 
survival and renal survival (survival without the need for renal replacement therapy) 
rates, as well as quality of life, including work disability.3 The glomerulus is the 
most common site of kidney involvement by lupus. However, the renal interstitium 
and tubules, as well as the vasculature, may also be affected.4 Early recognition of 
renal disease and close monitoring for progress after treatment is an essential part of 
  management. Conventional serological markers and clinical renal parameters for active 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
213
REvIEW
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJWH.S28034International Journal of Women’s Health 2012:4
lupus nephritis are not sensitive or specific enough, and novel 
biomarkers for early detection of renal disease and prediction 
of renal prognosis are under current evaluation.5
In this review, the prevalence, presentation, and treatment 
of lupus renal disease is summarized based on information 
from recent clinical observation and controlled trials.
How common is renal disease  
in SLE?
Lupus renal disease appears to be more prevalent in   certain 
ethnic groups.6,7 A comparative study of SLE in three   ethnic 
groups reported that renal disease, which is defined by 
  American College of Rheumatology (ACR) criteria as persis-
tent daily proteinuria of .500 mg in the presence of cellular 
casts or biopsy evidence of lupus nephritis, occurred in 45% 
of African Americans, 42% of Chinese, and 30% of Caucasian 
patients, respectively.6  Another multi-ethnic US cohort of SLE 
patients reported that renal disease occurred in 51% of Africans 
and 43% of Hispanics but in only 14% of   Caucasians.8 In a 
prospective study of 216 Chinese patients with new onset SLE, 
31% patients had active renal disease as the   initial   presentation.9 
The overall cumulative incidence of renal   disease was 60% at 5 
years post-SLE diagnosis. These studies illustrated that lupus 
renal involvement is more common in Africans, Hispanics, 
and Chinese than in Caucasians.
Clinical presentation of lupus 
nephritis
The presentation of renal disease in SLE is variable,   ranging 
from no symptoms (detected by routine renal biopsy or 
“silent” lupus nephritis), trace proteinuria or active urinary 
sediments (microscopic hematuria, pyuria or cellular casts), 
to more serious proteinuria (nephrotic syndrome) and acute 
nephritic syndrome with rapid progression to acute renal 
failure. Occasionally, patients may present with chronic renal 
failure, isolated renal insufficiency, and hypertension as the 
initial manifestation.
The wide range of presentations of lupus nephritis does 
not necessarily correlate with the renal histological findings. 
A retrospective study of  21 SLE patients with low levels of pro-
teinuria (,1 g/day) who underwent renal biopsy showed that 
proliferative lupus nephritis was present in 57% of patients.10 
This emphasizes the importance of renal biopsy, especially for 
new onset renal disease with active lupus serology.
The value of renal biopsy
Renal biopsy is the gold standard of confirming the diag-
nosis and flare of lupus glomerulonephritis. The finding of 
positive staining for immunoglobulin G, A, and M with 
C1q, C3, and C4 constitutes the “full house” staining pat-
tern for lupus nephritis. In addition, in guiding therapeutic 
decisions, renal biopsy provides information on the histo-
logical classes of lupus nephritis, in addition to the degree 
of inflammation and damage in the kidneys. Renal biopsy 
should be considered in SLE patients with new onset of 
proteinuria of more than 1 g/day with and without active 
urinary sediments, particularly in the presence of active 
lupus serology or impaired renal function. Some experts 
recommend renal biopsy at a lower threshold of proteinuria 
(eg, $500 mg/day).
Patients with lupus nephritis that is refractory to treat-
ment should be evaluated for other possible causes for the 
persistence of proteinuria or deterioration in renal function, 
such as the nephrotoxic side effects of medications (eg, the 
calcineurin inhibitors and nonsteroidal anti-inflammatory 
drugs), renal vein thrombosis, infections, overdiuresis, and 
poorly controlled hypertension. Treatment compliance should 
be checked. A repeat renal biopsy should be considered in 
patients with persistently active serological markers because 
it provides information on the following: (1)   histological 
transformation of the classes of lupus nephritis; (2) the 
degree of residual activity in the kidneys; and (3) the extent 
of chronic irreversible changes and their progression since 
the initiation of immunosuppressive treatment. These data 
may help guide further treatment decisions.
Prognosis of lupus nephritis
Lupus nephritis carries significant morbidity and mortality. In 
the 1990s, the renal survival (survival without dialysis) rates 
of lupus nephritis ranged from 83% to 92% in 5 years and 74% 
to 84% in 10 years.3,11–13 The risks of end stage renal failure 
were particularly high in patients with diffuse proliferative 
glomerulonephritis, with figures ranging from 11% to 33% 
in 5 years.3,7,11,13–16 The prognosis of lupus nephritis depends 
on a large number of demographic, racial, genetic, histo-
pathological, immunological, and time-dependent factors.17 
Renal disease that fails to remit with immunosuppressive 
therapies is a major risk factor for subsequent deterioration 
of renal function and poor outcome.3,16,18 Other unfavorable 
prognostic factors for lupus nephritis include younger age, 
male sex, histological cellular crescents, fibrinoid necrosis, 
subendothelial deposits, glomerular scarring, tubular atrophy 
and interstitial fibrosis, impaired renal function at presenta-
tion, persistent hypertension, hypocomplementemia, low 
hematocrit, in addition to delay in treatment due to limited 
access to health care and poor compliance.17
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
214
MokInternational Journal of Women’s Health 2012:4
Table 1 ISN/RPS histological classification of lupus nephritis21
Class I Minimal mesangial lupus nephritis
Normal glomeruli by light microscopy, but mesangial immune deposits by immunofluorescence.
Class II Mesangial proliferative lupus nephritis
Purely mesangial hypercellularity of any degree or mesangial matrix expansion by light microscopy, with mesangial immune deposits. 
A few isolated subepithelial or subendothelial deposits may be visible by immunofluorescence or electron microscopy, but not by 
light microscopy.
Class III Focal lupus nephritis
Active or inactive focal, segmental or global endo- or extracapillary glomerulonephritis involving ,50% of all glomeruli, typically with 
focal subendothelial immune deposits, with or without mesangial alterations.
Class IV Diffuse lupus nephritis
Active or inactive diffuse, segmental or global endo- or extracapillary glomerulonephritis involving $50% of all glomeruli, typically 
with diffuse subendothelial immune deposits, with or without mesangial alterations. This class is divided into diffuse segmental (Iv-S) 
lupus nephritis when $50% of the involved glomeruli have segmental lesions, and diffuse global (Iv-G) lupus nephritis when $50% of 
the involved glomeruli have global lesions. Segmental is defined as a glomerular lesion that involves less than half of the glomerular 
tuft. This class includes cases with diffuse wire loop deposits but with little or no glomerular proliferation.
Class V Membranous lupus nephritis
Global or segmental subepithelial immune deposits or their morphologic sequelae by light microscopy and by immunofluorescence 
or electron microscopy, with or without mesangial alterations.
Class v lupus nephritis may occur in combination with class III or Iv in which case both will be diagnosed.
Class VI Advanced sclerotic lupus nephritis
$90% of glomeruli globally sclerosed without residual activity.
Abbreviation: ISN/RPS, International Society of Nephrology/Renal Pathology Society. Data drawn from Weening JJ, D’Agati vD, Schwartz MM, Seshan Sv, Alpers CE, Appel 
GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–250.21
Contemporary treatment of lupus 
nephritis
Therapy for lupus nephritis should aim at symptomatic 
control, preservation of renal function, reduction of renal 
flares, prevention of treatment-related complications, and 
ultimately, reduction in mortality.19 Immunosuppressive 
therapy for lupus nephritis is divided into two phases: 
the induction phase targets reducing inflammation and 
glomerular injury; and the maintenance phase aims to 
reduce long-term risks of renal flares and renal function 
decline.
Adjunctive therapies, such as vigorous control of blood 
pressure to ,120/80 mmHg, may retard the deterioration of 
renal function. The early use of renal protection agents, such 
as the angiotensin converting enzyme inhibitors (ACEIs) 
and the angiotensin II receptor antagonists, is mandatory. 
Hyperlipidemia should also be controlled to offer protec-
tion against accelerated vascular disease, particularly in 
the membranous type of lupus nephritis. Calcium and 
vitamin D should be adequately supplemented to reduce the 
risk of aggravation of disease activity related to vitamin D 
deficiency,20 and to protect against osteoporosis. Low-dose 
aspirin may be considered in patients with histological evi-
dence of antiphospholipid syndrome nephropathy, although 
there is no published evidence to support this treatment. 
Anticoagulation may be considered in patients with per-
sistent nephrotic ranges of proteinuria and the presence of 
antiphospholipid antibodies.
Induction therapy of lupus 
nephritis
The current histological classification of lupus nephritis is 
based on the recommendation of the International Society 
of Nephrology/Renal Pathology Society (ISN/RPS) in 2003 
(Table 1).21 Milder forms of lupus nephritis (ISN/RPS Class I, 
II) are usually manageable with glucocorticoids.22 Azathioprine 
(AZA) can be added as a glucocorticoid-sparing agent and for 
the treatment of concomitant extra-renal manifestations. Mild 
class V disease can be treated with ACEIs. Proliferative lupus 
nephritis (class III and IV or mixed III/V and IV/V) and more 
serious class V (nephrotic range of proteinuria or deteriorat-
ing renal function) disease require more aggressive induction 
regimens that combine glucocorticoid and a non-glucocorticoid 
immunosuppressive agent. The standard induction therapy for 
severe lupus nephritis has been a combination of high-dose 
glucocorticoid and cyclophosphamide (CYC). A series of ran-
domized controlled trials conducted by the National Institute 
of Health (NIH) demonstrated that prednisone combined with 
intravenous (IV) pulse CYC offered better long-term renal 
protection than prednisone monotherapy.23–25 However, the use 
of CYC is associated with a number of untoward side effects, 
which include infection, ovarian and bladder toxicities, leuko-
penia, increased risk of cervical intraepithelial neoplasia, and 
malignancy. Some of these toxicities are dose dependent, with 
higher risks related to higher cumulative doses.26 IV pulse CYC 
has gained popularity over daily oral CYC because it is associated 
with less toxicity in the bladder and the gonads. A recent analysis   
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of a large cohort of patients with diffuse proliferative lupus 
nephritis showed a trend towards better efficacy of oral CYC 
than IV pulse CYC in preserving renal function after a mean 
follow-up of 8.8 years.18 In a multivariate model, a dose 
of CYC delivered cumulatively instead of the CYC route 
per se was independently associated with a complete renal 
response. However, ovarian toxicity leading to premature meno-
pause was more frequent in users of oral CYC.
Although the optimal route and duration of CYC therapy 
in lupus nephritis remains uncertain, recent evidence sup-
ports the use of a shorter course and lower dose of CYC 
to minimize toxicities.27–29 Houssiau et al29 compared the 
efficacy and toxicity of two less intensive intravenous pulse 
CYC regimens for the initial treatment of lupus nephritis. 
Eighty-four patients (predominantly Caucasians) were 
randomized to receive either 8 intravenous pulses of CYC 
(0.5 g/m2 to a maximum of 1.5 g) or 6 biweekly low dose 
pulses of CYC (500 mg each). In both regimens, CYC was 
later substituted with AZA for long-term maintenance. 
Patients who participated in the study had milder renal 
disease compared to other lupus nephritis trials, as reflected 
by a lower proportion of patients having class IV disease, 
nephrotic syndrome, and renal function impairment. After 
10 years, mortality, sustained doubling of serum creatinine, 
and end stage renal disease did not differ between the two 
groups.29 Thus, when there are no alternatives to CYC, 
a low-dose CYC regimen followed by AZA is a viable strat-
egy for milder lupus   nephritis. CYC is reserved for high-risk 
patients with proliferative lupus nephritis, such as those with 
impaired or rapidly deteriorating renal function, histologi-
cal cellular crescents, or a combination of high activity and 
chronicity scores.30 The course of CYC should be limited to 
less than 6 months, with subsequent replacement by another 
immunosuppressive agent to reduce toxicities.28
Controlled trials for induction 
therapy of lupus nephritis
Six randomized controlled trials for induction therapy of 
severe lupus nephritis were recently presented (Table 2).31–36 
In the largest lupus nephritis controlled trial to-date, the 
Aspreva Lupus Management Study (ALMS), 370 patients 
with histologically ISN/RPS class III, IV , or V lupus nephri-
tis (2/3 class IV disease) were randomized to receive either 
monthly IV pulse CYC (0.5–1.0 g/m2) or MMF (target 
3 g/day) on top of high-dose prednisone (60 mg/day initially 
and then tapered).31 Asians and Hispanics comprised 33% 
and 35% of the participants, respectively. Three hundred 
and six (83%) patients completed the 24-week protocol. 
Clinical response, defined by a decrease in urine protein/ 
creatinine ratio (P/Cr) to ,3 in patients with baseline nephrotic 
range P/Cr $ 3, or by $50% in patients with subnephrotic 
baseline P/Cr (,3), and stabilization (±25%) or improvement 
in serum creatinine at 24 weeks as adjudicated by a blinded 
clinical endpoints committee, was not significantly different 
between the CYC (53%) group and the MMF (56%) group. 
Subgroup analyses revealed that MMF was associated with 
a significantly higher response rate than CYC (60% vs 39%; 
P = 0.03) in the non-Caucaisan non-Asians, who were mainly 
Hispanics. The rates of adverse events and serious adverse 
events were similar in the two groups. Specifically, nausea, 
vomiting, and alopecia were numerically more frequent with 
CYC, whereas diarrhea was more commonly reported in 
MMF users. There were 9 and 5 deaths in the MMF group 
and the CYC group, respectively. Of the 9 deaths in the 
MMF users, 7 were Asians (mainly Chinese), suggesting 
that Asian patients tolerated high-dose prednisone and MMF 
(3 g/day) less well.
Grootscholten et al32 randomized 87 patients with pro-
liferative lupus nephritis (class III and IV) to receive either 
oral prednisone combined with intravenous pulse CYC 
(750 mg/m2 monthly for 6 months and then quarterly for 
another 7 doses) or intravenous pulse methylprednisolone 
(1 g daily for 3 days for 9 pulses) together with AZA 
(2 mg/kg/day). At the end of the third year, both groups of 
patients received AZA for maintenance (2 mg/kg/day), with 
the dosage reduced to 1 mg/kg/day after 4 years. This study 
consisted of mainly Caucasian patients (76%) who had serious 
renal disease (57% hypertension, 53% nephrotic syndrome, 
and 56% impaired creatinine clearance at presentation). After 
a median of 5 years, significantly more AZA-treated patients 
relapsed, and a numerically higher number of patients had 
renal function deterioration. Despite the use of a more inten-
sive corticosteroid regimen in the AZA arm, the outcome was 
less satisfactory, indicating that AZA was inferior to CYC 
for more severe lupus nephritis.
Bao et al33 randomized 40 patients with mixed prolif-
erative and membranous lupus nephritis (ISN/RPS IV + V) 
(85% of patients with normal serum creatinine) to receive 
either IV pulse CYC (0.5–1 g ⋅ m2 monthly) (N = 20) or 
low-dose combination of MMF (500 mg BD) and tacroli-
mus (Tac) (2 mg BD) (N = 20), in addition to corticos-
teroids (daily pulse methylprednisolone 0.5 g for 3 days, 
followed by 0.6–0.8 mg/kg/day of oral prednisolone). At 
6 months, the rate of complete response defined as daily 
  proteinuria , 0.4 g/day with normal urinary sediments 
and stabilization of serum creatinine (,15% increase) was 
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  significantly higher in the MMF/Tac (50%) group than the 
CYC (5%) group. The corresponding rates at 9 months of 
treatment were 65% and 15%, respectively. Leukopenia, gas-
trointestinal upset, upper respiratory tract infection,   alopecia, 
and irregular menses were more common in the CYC group 
than in the MMF/Tac group of patients.
In a randomized controlled trial conducted recently by 
Chen et al,34 81 patients with class III, IV , or V lupus nephri-
tis were randomized to receive IV pulse CYC (0.5–1 g ⋅ m2 
monthly) (N = 39) or Tac (0.05 mg/kg/day titrating to a 
level of .5 ng/mL) (N = 42) in combination with high-
dose prednisolone (1 mg/kg/day). The study population 
consisted of moderate to high-risk patients (77% class IV 
disease and 11% impaired renal function at presentation). 
At 6 months, the rate of complete remission, which was 
defined as   proteinuria , 0.3 g/day, stabilization of serum 
creatinine, and normalization of urinary sediments, was not 
significantly different in the CYC group and the Tac group 
of patients (38% vs 52%, P = 0.2). Gastrointestinal upset 
and leucopenia were significantly more frequent in the CYC 
group, but the rate of infection was similar between the two 
arms. Transient increase in serum creatinine was reported in 
8% of patients receiving Tac.
Our group conducted a controlled trial comparing the 
efficacy of MMF (2 g/day, titrating to 3 g/day if response 
is suboptimal at 3 months) with Tac (0.1 mg/kg/day in the 
first 2 months tapering to 0.06 mg/kg/day) in combination 
with high-dose prednisolone (0.6 mg/kg/day for 6 weeks 
and taper) for lupus nephritis.35 Our preliminary analysis of 
130 patients showed that both complete and partial clinical 
response rates were not significantly different between the 
two treatment arms at 6 months. The rate of infection, in 
particular herpes zoster reactivation, was higher in MMF 
than in Tac-treated patients, whereas alopecia, tremor, and 
reversible increase in serum creatinine were more frequent 
in the Tac group of patients. Dose-related neurological and 
metabolic adverse effects of Tac and the possibility of early 
renal relapse upon completion of the induction phase and 
substitution of Tac must be carefully monitored.
The Lupus Nephritis Assessment with Rituximab 
(LUNAR) study is a phase III randomized, double-blind, 
placebo-controlled multicenter study to evaluate the efficacy 
and safety of rituximab in patients with active proliferative 
lupus nephritis.36 Patients with ISN/RPS Class III or IV lupus 
nephritis and urine protein to creatinine (UP/Cr) ratio . 1 
were randomized to receive rituximab (1000 mg) (N = 72) or 
placebo (N = 72) infusion on days 1, 15, 168 (week 24) and 182 
(week 26), in addition to corticosteroid and MMF (.2 g/day). 
Two-thirds of the patients had class IV   nephritis. At week 52, 
no statistically significant differences in the primary and 
secondary endpoints were observed between the   rituximab 
and placebo groups of patients, although there were numeri-
cally more responders in the rituximab group (57% vs 
46% in the placebo group), mainly among Africans and 
  Hispanics.   Serious adverse events and infection rates were 
similar between the two groups, but two deaths occurred in 
the rituximab-treated patients.
The information reviewed indicates that MMF should 
be used as the first-line treatment in combination with 
glucocorticoids for severe lupus nephritis because of the 
stronger evidence for it compared to other agents and the 
lower incidence of toxicities compared to conventional CYC. 
Although Tac has similar efficacy with either CYC or MMF, 
it has been tried in a smaller population of patients, and its 
long-term nephrotoxicity remains a concern. However, Tac 
is an option when patients are contraindicated for, intolerant 
to, or refractory to MMF. Tac is preferred to cyclosporin 
A because of the lower incidence of cosmetic side effects, 
particularly in young women. The initial results of the B cell 
depleting agents are disappointing. Although evidence does 
not support an additional benefit of rituximab, with MMF 
treatment for lupus nephritis, rituximab is still an option for 
recalcitrant lupus nephritis, as evidenced by a number of 
case series.37–39
Maintenance therapy of lupus 
nephritis
Indirect evidence suggests that maintenance therapy is ben-
eficial in severe lupus nephritis. In a long-term follow-up of 
145 patients who participated in NIH lupus nephritis studies, 
renal flares occurred in 45% of patients when immunosup-
pression was completely stopped.40 A recent retrospective 
review of 32 patients with predominantly diffuse proliferative 
lupus nephritis described a relapse of lupus activity in 53% 
of patients after immunosuppression was discontinued.41 In 
our experience with 212 patients with diffuse proliferative 
lupus nephritis,18 although maintenance treatment was given 
to 73% of patients, one-third of patients still had renal flares 
that might be serious. Maintenance therapy for ,3 years 
was independently associated with an increased likelihood 
of having the composite outcome of doubling of serum 
creatinine, end stage renal failure, or death (hazard ratio 4.62 
[1.35–15.8]; P = 0.02).
In Moroni’s study,41 patients who experienced sustained 
remission of lupus nephritis had received a longer total 
median duration of immunosuppressive treatment than those 
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who did not (median 57 months vs 30 months; P , 0.01). 
This finding, coupled with the observation that maintenance 
treatment for ,3 years after successful CYC induction was 
a predictor of poor renal outcome in proliferative lupus 
nephritis,18 suggests that maintenance immunosuppression 
should be continued for at least 3 years after a good clinical 
response is achieved.
Four randomized controlled trials on maintenance therapy 
of lupus nephritis are summarized in Table 3. Contreras et al42 
randomized 59 patients with lupus nephritis (mainly African 
and Hispanic Americans; 78% had class IV disease) to receive 
one of the three treatment arms after induction with 4–7 pulses 
of intravenous CYC: (1) MMF (0.5–3 g/day); (2) quarterly 
pulse CYC; (3) AZA (1–3 mg/kg/day). Long-term observation 
showed that either MMF or AZA was superior to CYC in the 
prevention of the composite outcome of renal failure and death. 
MMF was more efficacious than pulse CYC in the prevention 
of renal flares. Moreover, maintenance treatment with CYC 
was associated with more side effects such as nausea, vomiting, 
and infection. Moroni et al43 studied 69 patients (mainly Cau-
casians) with lupus nephritis. After initial induction treatment 
with pulse methylprednisolone, prednisone, and oral CYC 
(91.5 ± 23.8 mg/day for a median of 3 months), patients were 
randomized to receive either cyclosporin A (CSA) (Neoral; 
4.0 to 2.5–3.0 mg/kg/day) (N = 36) or AZA (2 mg/kg/day) 
(N = 33) for maintenance. At 4 years of follow-up, flare 
occurred in 24% of AZA-treated patients and 19% of CSA-
treated patients, respectively (no significant difference). Minor 
infections and leucopenia were more commonly reported with 
AZA treatment, whereas arthralgia and gastrointestinal symp-
toms were more common in CSA-treated patients.
In the MAINTAIN study conducted by Houssiau et al,44 
105 patients with class III, IV , Vc and Vd lupus nephritis 
were randomized to receive either MMF (2 g/day) (N = 53) 
or AZA (2 mg/kg/day) (N = 52) after an initial induction 
regimen that consisted of IV pulse methylprednisolone, high-
dose prednisone and IV pulse CYC (500 mg twice weekly 
for 6 doses). Participants were mainly Caucasians, and 10% 
of patients had impaired renal function at study entry. After 
a mean follow-up of 53 (15–65) months, 24 (23%) patients 
withdrew from the study mainly because of pregnancy 
(in the MMF group) and adverse effects. Frequency of 
renal and extra-renal flares, doubling of serum creatinine, 
and incidence of infections occurred at similar frequency in 
the two arms. However, drug-related cytopenias were more 
common with AZA.
The maintenance phase of the ALMS study was recently 
published.45 Two hundred and twenty-seven patients 
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(44% Whites, 10% Blacks, and 33% Asians) who had 
completed the induction phase of the ALMS (IV pulse CYC 
or MMF 3 g/day) were randomized to receive either MMF 
(2 g/day) (N = 116) or AZA (2 mg/kg/day) (N = 111) for 
maintenance treatment. The mean daily doses received by the 
patients were 1.87 ± 0.43 g and 120 ± 48 mg, respectively, 
for MMF and AZA. After a mean follow-up of 2.1 years, the 
rate of treatment failure, defined as renal flare, doubling of 
serum creatinine, or end stage renal disease, needed for res-
cue therapy or death was significantly less common in MMF 
than in AZA-treated patients (16.4% vs 32.4%; P = 0.003). 
The results were similar regardless of induction by CYC or 
MMF, race, or geographical region.
In summary, it appears that MMF is the preferred agent 
for long-term maintenance therapy of lupus nephritis. 
  However, its cost-effectiveness should be further evaluated. 
AZA and CSA are alternative options for patients who are 
intolerant to MMF or are planning for pregnancy. The long-
term use of calcineurin inhibitors, such as Tac and CSA, must 
be cautious because of the increased risk of nephrotoxicity, 
hyperlipidemia, and atherosclerosis.
Membranous lupus nephropathy
Membranous lupus nephropathy (MLN) comprises only one-
fifth of all cases of histologically confirmed lupus nephritis.46 
Reported rates of patient survival and end-stage renal disease 
in MLN vary considerably because of substantial heterogene-
ity among the published studies. The risk of progression of 
MLN to renal failure is generally reduced in the absence of 
proliferative lesions, but patients are nevertheless at risk for 
thromboembolic complications.
The optimal therapy for MLN remains elusive because 
of the paucity of clinical trials. Mixed membranous and 
proliferative lupus nephritis should be treated in the same 
way as pure proliferative lupus nephritis. If MLN is not 
accompanied by proliferative lesions but is associated with 
clinically relevant proteinuria, renal insufficiency, or failure 
to respond to supportive therapies, immunosuppressive treat-
ment is indicated. In addition, cardiovascular protection and 
blockade of the renin-angiotensin system should be instituted 
early in all patients.
Austin et al47 randomized 42 patients (71% Blacks 
or Hispanics) with MLN to receive one of the following 
regimens: (1) alternate day prednisone (1 mg/kg/day for 
8 weeks and taper to 0.25 mg/kg/day throughout); (2) similar 
prednisone regimen plus IV pulse CYC (0.5–1.0 g/m2 every 
two months); or (3) similar prednisone regimen plus CSA 
(5 mg/kg/day). At 12 months, the cumulative probability of 
complete (,0.3 g/day proteinuria) or partial (,2.0 g/day 
proteinuria or improvement by 50% from baseline) remission 
was highest with CSA (83%), followed by IV pulse CYC 
(60%) and prednisone alone (27%). The response rates of 
either CSA or CYC were significantly better than prednisone 
monotherapy. However, relapse of nephrotic syndrome was 
significantly more common after discontinuation of treatment 
with CSA than after IV pulse CYC. Adverse effects during 
the 12-month period included insulin-requiring diabetes (one 
with prednisone and two with CSA), pneumonia (one with 
prednisone and two with CSA), and localized herpes zoster 
(two with IVCY).
A recent pooled analysis of 65 patients with pure MLN 
recruited for two randomized controlled trials and who had 
completed 24 weeks of treatment31,48 showed no differences 
in the measured end points, response rate, mortality, and 
withdrawal rate between MMF and IV pulse CYC.49 There 
was also no difference in the change in proteinuria or par-
tial response rate between MMF and CYC in those patients 
presenting with nephritic syndrome.
In summary, more serious MLN should be treated with 
a combination of glucocorticoid and a non-glucocorticoid 
immunosuppressive agent. A number of uncontrolled open 
series have reported efficacy of various regimens for MLN, 
such as AZA, tacrolimus, and MMF in combination with 
glucocorticoids.46 Many specialists start with MMF or AZA 
for MLN because of their lower incidence of adverse effects, 
reserving other agents such as IV pulse CYC, CSA, and 
tacrolimus for salvage therapy when the clinical response 
is not optimal. Newer agents, such as rituximab, infliximab, 
and sirolimus, should be further studied in MLN.37
Conclusion
Renal involvement is a major determinant of the prognosis 
of SLE. Treatment of lupus nephritis should target disease 
remission, prevention of relapse and complications, and 
long-term preservation of renal function. MMF combined 
with prednisone has emerged as the first-line treatment. CYC 
is reserved for more serious or refractory cases of lupus 
nephritis. The evidence for calcineurin inhibitors in lupus 
nephritis is less strong and they are reserved for patients 
intolerant or recalcitrant to MMF. While further evidence 
from controlled trials is eagerly awaited, the current use of 
B cell modulating agents is confined to recalcitrant renal 
disease. Novel biomarkers are being explored for earlier 
detection of renal flares and better prognostic stratification so 
that intervention can be instituted early to minimize damage 
to renal function.
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